In the BioHarmony Drug Report Database
Eptinezumab
Vyepti (eptinezumab) is an antibody pharmaceutical. Eptinezumab was first approved as Vyepti on 2020-02-21. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1 and calcitonin gene-related peptide 2.
Trade Name
|
Vyepti |
|---|---|
Common Name
|
eptinezumab |
ChEMBL ID
|
CHEMBL3833320 |
Indication
|
|
Drug Class
|
Monoclonal antibodies: humanized, neural indications |
Image (chem structure or protein)
